Patient group input submissions: Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Two questionnaires (February & March 2016) were promoted via CSPA's social media channels to psoriasis patients or those suffering with psoriasis related symptoms (44 surveys received) to gather input on the effectiveness of ixekizumab in the treatment of the disease
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 2017 Sep
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Two questionnaires (February & March 2016) were promoted via CSPA's social media channels to psoriasis patients or those suffering with psoriasis related symptoms (44 surveys received) to gather input on the effectiveness of ixekizumab in the treatment of the disease |
|---|---|
| Physical Description: | 1 PDF file (7 pages) illustrations |